Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation

Keio Journal of Medicine

Volumn 52, Issue 3, 2003, Pages 182-188

  Ullmann, Andrew J ^a,d   Hess, Georg ^a   Kolbe, Karin ^a   Friedrich Freksa, A ^b   Meyer, Ralf G ^a   Gschaidmeier, Harald ^c   Huber, Christoph ^a   Fischer, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Germany   (Germany)

^c Clinical Research and Development   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Allogeneic; Imatinib mesylate; STI 571; Syngeneic; Transplantation

Indexed keywords

BCR ABL PROTEIN; CD3 ANTIGEN; CYCLOSPORIN A; IMATINIB; INTERFERON; MESSENGER RNA; PREDNISOLONE; PROTEIN TYROSINE KINASE INHIBITOR; STEROID;

ADULT; ALLOTRANSPLANTATION; ANEMIA; ARTICLE; ASPERGILLOSIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CHIMERA; CHRONIC MYELOID LEUKEMIA; COLITIS; CYTOGENETICS; CYTOPENIA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; EVALUATION; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; GRANULOCYTOPENIA; HEMATOLOGICAL PARAMETERS; HEMATOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; HYGROMA; HYPOPLASIA; INCIDENCE; INFUSION; ISOTRANSPLANTATION; LEUKEMIA; LIVER TOXICITY; LIVING DONOR; LYMPHOCYTE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MUSCLE CRAMP; NEUTROPENIA; OUTCOMES RESEARCH; PATIENT MONITORING; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; RASH; RECIPIENT; THROMBOCYTOPENIA;

EID: 0141756260     PISSN: 00229717     EISSN: None     Source Type: Journal    
DOI: 10.2302/kjm.52.182     Document Type: Article

References (32)

1. Goldman JM, Druker BJ: Chronic myeloid leukemia: current treatment options. Blood 2001; 98: 2039-2042
2. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, Frassoni F, Gahrton G, Kolb HJ, Niederwieser D, et al: Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087-1092
3. Dazzi F, Szydlo RM, Goldman JM: Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol 1999; 27: 1477-1486
4. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, et al: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050
5. Roman J, Alvarez MA, Torres A: Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation. Haematologica 2000; 85: 1072-1082
6. Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, et al: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444
7. Dazzi F, Szydlo RM, Craddock C, Cross NC, Kaeda J, Chase A, Olavarria E, van Rhee F, Kanfer E, Apperley JF, et al: Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 67-71
8. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP, Kernan NA, et al: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261-1268
9. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566
10. Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, Di Nicola M, Biondi A, Corneo GM, Belotti D, et al: Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997; 23: 380-394
11. le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F, Gambacorti-Passerini C: In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1999; 91: 163-168
12. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652
13. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530-3539
14. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, et al: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-1937
15. Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J, Giles FJ, Thomas DA, Faderl S, De Lima M, et al: Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100: 1590-1595
16. Rodriguez R, Snyder D, Nademanee A, O'Donnell M, Krishnan A, Bhatia R, Slovak M, Resta D, Forman S: Gleevec for relapsed CML after allogeneic transplant may overcome need for donor leukocyte infusions (DLI) or interferon (IFN). Blood 2001; 98: abstract 1684
17. Au WY, Lie AK, Ma SK, Wan TS, Liang R, Chan EC, Kwong YL: Tyrosine kinase inhibitor STI571 in the treatment of Philadelphia chromosome-positive leukaemia failing myeloablative stem cell transplantation. Bone Marrow Transplant 2002; 30: 453-457
18. Chambon-Pautas, Cony-Makhoul P, Giraudier S, Vigier M, Michallet M, Guilhot F, Jouet JP, Berthaud P, Kuentz M: Glivec (STI571) Treatment for chronic myelogenous leukemia (CML) in relapse after allogeneic stem cell transplantation (SCT): a report of the French experience (on behalf of the SFGM and FILMC). Blood 2001; 98: abstract 587
19. Kantarjian HM, O'Brien S, Cortes J, Giralt S, Beth Rios M, Shan J, Giles F, Thomas D, Faderl S, de Lima M, et al: Results of imatinib mesylate (STI571) therapy in patients (pts) with chronic myelogenous leukemia (CML) in relapse after allogeneic stem cell transplantation (allo SCT). Blood 2001; 98: Abstract 575
20. Ottmann OG, Wassmann B, Pfeifer H, Scheuring U, Thiede C, Brueck P, Binckebank A, Atta J, Martin H, Gschaidmeier H, et al: Activity of the ABL-tyrosine kinase inhibitor glivec (STI571) in Philadelphia chromosome positive acute lymphoblastic leukemia (PH+ALL) relapsing after allogeneic stem cell transplantation (allo-SCT). Blood 2001; 98: abstract 2470
21. Pfeifer H, Wassmann B, Scheuring U, Binckebanck A, Atta J, Brück P, Martin H, Bartmann M, Gschaidmeier H, Thiede C, et al: STI571 (Glivec) in the treatment of patients with chronic myeloid leukemia (CML) relapsing after allogeneic stem cell transplantation (allo SCT). Bone Marrow Transplantation 2002; 29 Supple 2: S34
22. Soiffer RJ, Galinsky I, DeAngelo D, Alyea EP, Antin JH, Restas D, Stone RM: Imatinib mesylate (Gleevec) for disease relapse following allogeneic bone marrow transplantation. Blood 2001; 98: abstract 1682
23. Ullmann AJ, Beck J, Kolbe K, Gschaidmeier H, Meinhardt PL, Huber C, Fischer T: Clinical and laboratory evaluation of patients treated with STI-571 (Gleevec™) after allogeneic and syngeneic stem cell transplantation with relapsed Philadelphia chromosome-positive leukemia. Blood 2001; 98: abstract 1685
24. Ullmann AJ, Beck J, Meinhardt P, Gschaidmeier H, Huber C, Fischer T: STI-571 in patients with relapsed Philadelphia chromosome-positive leukemia after allogeneic or syngeneic SCT. Bone Marrow Transplantation 2002; 27 Supple 1: P433
25. Wassmann B, Pfeifer H, Scheuring U, Brueck P, Binckebank A, Atta J, Martin H, Gschaidmeier H, Thiede C, Bornhauser M, et al: Glivec (STI571) in the treatment of patients with chronic myeloid leukemia (CML) relapsing in accelerated or blastic phase after allogeneic stem cell transplantation. Blood 2001; 98: abstract 588
26. Wassmann B, Pfeifer H, Scheuring U, Thiede C, Atta J, Klein SA, Martin H, Bartmann M, Gschaidmeier H, Brück P, et al: Efficacy of the ABL-tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+All) relapsing after allogeneic stem cell transplantation (Allo SCT). Bone Marrow Transplantation 2002; 29: Supple 2, S6
27. Hess G, Reifenrath C, Friedrich-Freksa A, Beyer V, Naumann S, Schuch B, Huber C, Fischer T, Decker HJ: Autologous transplantation of in vivo purged PBSC in CML: comparison of FISH, cytogenetics, and PCR detection of Philadelphia chromosome in leukapheresis products. Cancer Genet Cytogenet 2000; 117: 1-8
28. Preudhomme C, Revillion F, Merlat A, Hornez L, Roumier C, Duflos-Grardel N, Jouet JP, Cosson A, Peyrat JP, Fenaux P: Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay. Leukemia 1999; 13: 957-964
29. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037
30. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M: Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 1995; 122: 254-261
31. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NC, Hochhaus A: Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999; 13: 1825-1832
32. Weisser A, La Rosée P, Burmeister T, et al: Sensitivity, quality and comparability of bcr-abl quantification by RT-PCR: results of an interlaboratory analysis. Blood 2001; 98: Abstract 1352